Search Page

1

Cite

Share

Children's Oncology Group's 2013 blueprint for research: neuroblastoma.

Park JR, Bagatell R, London WB, Maris JM, Cohn SL, Mattay KK, Hogarty M; COG Neuroblastoma Committee. Park JR, et al. Among authors: hogarty m. Pediatr Blood Cancer. 2013 Jun;60(6):985-93. doi: 10.1002/pbc.24433. Epub 2012 Dec 19. Pediatr Blood Cancer. 2013. PMID: 23255319 Review.

Cite

Share

2

Cite

Share

Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children's Cancer Group study.

Maris JM, Weiss MJ, Guo C, Gerbing RB, Stram DO, White PS, Hogarty MD, Sulman EP, Thompson PM, Lukens JN, Matthay KK, Seeger RC, Brodeur GM. Maris JM, et al. Among authors: hogarty md. J Clin Oncol. 2000 May;18(9):1888-99. doi: 10.1200/JCO.2000.18.9.1888. J Clin Oncol. 2000. PMID: 10784629

Cite

Share

3

Cite

Share

Localization of a hereditary neuroblastoma predisposition gene to 16p12-p13.

Weiss MJ, Guo C, Shusterman S, Hii G, Mirensky TL, White PS, Hogarty MD, Rebbeck TR, Teare D, Urbanek M, Brodeur GM, Maris JM. Weiss MJ, et al. Among authors: hogarty md. Med Pediatr Oncol. 2000 Dec;35(6):526-30. doi: 10.1002/1096-911x(20001201)35:6<526::aid-mpo5>3.0.co;2-s. Med Pediatr Oncol. 2000. PMID: 11107108

Cite

Share

4

Cite

Share

Comprehensive analysis of chromosome 1p deletions in neuroblastoma.

Maris JM, Guo C, Blake D, White PS, Hogarty MD, Thompson PM, Rajalingam V, Gerbing R, Stram DO, Matthay KK, Seeger RC, Brodeur GM. Maris JM, et al. Among authors: hogarty md. Med Pediatr Oncol. 2001 Jan;36(1):32-6. doi: 10.1002/1096-911X(20010101)36:1<32::AID-MPO1009>3.0.CO;2-0. Med Pediatr Oncol. 2001. PMID: 11464900

Cite

Share

5

Cite

Share

Targeting programmed cell death pathways with experimental therapeutics: opportunities in high-risk neuroblastoma.

Goldsmith KC, Hogarty MD. Goldsmith KC, et al. Cancer Lett. 2005 Oct 18;228(1-2):133-41. doi: 10.1016/j.canlet.2005.01.048. Cancer Lett. 2005. PMID: 15927359 Review.

Cite

Share

6

Cite

Share

Mutations in PIK3CA are infrequent in neuroblastoma.

Dam V, Morgan BT, Mazanek P, Hogarty MD. Dam V, et al. BMC Cancer. 2006 Jul 5;6:177. doi: 10.1186/1471-2407-6-177. BMC Cancer. 2006. PMID: 16822308 Free PMC article.

Cite

Share

7

Cite

Share

Survivin mRNA levels are associated with biology of disease and patient survival in neuroblastoma: a report from the children's oncology group.

Miller MA, Ohashi K, Zhu X, McGrady P, London WB, Hogarty M, Sandler AD. Miller MA, et al. Among authors: hogarty m. J Pediatr Hematol Oncol. 2006 Jul;28(7):412-7. doi: 10.1097/01.mph.0000212937.00287.e5. J Pediatr Hematol Oncol. 2006. PMID: 16825985

Cite

Share

8

Cite

Share

Immunosurveillance and survivin-specific T-cell immunity in children with high-risk neuroblastoma.

Coughlin CM, Fleming MD, Carroll RG, Pawel BR, Hogarty MD, Shan X, Vance BA, Cohen JN, Jairaj S, Lord EM, Wexler MH, Danet-Desnoyers GA, Pinkus JL, Pinkus GS, Maris JM, Grupp SA, Vonderheide RH. Coughlin CM, et al. Among authors: hogarty md. J Clin Oncol. 2006 Dec 20;24(36):5725-34. doi: 10.1200/JCO.2005.05.3314. J Clin Oncol. 2006. PMID: 17179106

Cite

Share

9

Cite

Share

Phase I Trial of G3139, a bcl-2 antisense oligonucleotide, combined with doxorubicin and cyclophosphamide in children with relapsed solid tumors: a Children's Oncology Group Study.

Rheingold SR, Hogarty MD, Blaney SM, Zwiebel JA, Sauk-Schubert C, Chandula R, Krailo MD, Adamson PC; Children's Oncology Group Study. Rheingold SR, et al. Among authors: hogarty md. J Clin Oncol. 2007 Apr 20;25(12):1512-8. doi: 10.1200/JCO.2006.09.5125. J Clin Oncol. 2007. PMID: 17442993 Clinical Trial.

Cite

Share

10

Cite

Share

Neuroblastoma.

Maris JM, Hogarty MD, Bagatell R, Cohn SL. Maris JM, et al. Among authors: hogarty md. Lancet. 2007 Jun 23;369(9579):2106-20. doi: 10.1016/S0140-6736(07)60983-0. Lancet. 2007. PMID: 17586306 Review.

Cite

Share